Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen and PATH to ally on HIV therapy development

Janssen and PATH to ally on HIV therapy development

27th September 2013

Janssen is to develop a new injectable treatment for HIV in association with PATH, the international non-profit global health organisation.

The firm's Irish research and development division has signed a licence agreement with PATH for the early development of the HIV-1 medicine rilpivirine in a long-acting injection as a potential pre-exposure prophylaxis (PrEP) treatment.

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor which is currently commercialised by Janssen for the oral once-daily treatment of HIV-1, in combination with other antiretroviral agents.

This new agreement will give PATH  the right to develop the rilpivirine long-acting formulation as a possible new way to prevent infection among uninfected individuals at high risk of acquiring the disease.

Wim Parys, global head of research and development at Janssen Global Health, said: "We believe that evaluating a long-acting formulation, which could help improve adherence in a PrEP regimen, is an important part of the Janssen commitment to the global fight against HIV and AIDS."

Earlier this year, Janssen highlighted data from a survey conducted among participants in a recent HIV drug trial it carried out, with most patients saying they would recommend their experience to others.ADNFCR-8000103-ID-801642890-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.